Resolution

Resolution Therapeutics was founded in August 2020 to develop engineered macrophage cell therapies.

Syncona founded Resolution following a two year collaboration with researchers at the University of Edinburgh. The company is developing macrophage cell therapies to repair organ damage, including treatment of end-stage chronic liver disease. Macrophages are cells of the innate immune system which orchestrate the body’s defence against infection and injury.

Pre-clinical

Company Details

CEO:

Edward Hodgkin

Founders:

Stuart Forbes
John Campbell

Syncona Representatives:

Martin Murphy
Edward Hodgkin
Gonzalo Garcia

Latest updates

There are currently no updates for Resolution.